Evidence mapPaperPMID 39910018Full record

SynthesisObesity surgery2025

The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis.

Joseph Kellett, Sara S Soliman, Alicia Podwojniak, Michelle Minkanic, Gaurav Kumar, Brandon Goodwin, Hyo J Yang, Jana K Elsawwah, Zoltan H Nemeth

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Weight Cycling Deregulates Eating Behavior in Mice via the Induction of Durable Gut Dysbiosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joseph KellettRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Sara S SolimanRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Alicia PodwojniakRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Michelle MinkanicRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Gaurav KumarRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Brandon GoodwinRowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Hyo J YangDepartment of Surgery, Morristown Medical Center, Morristown, NJ, USA.
Jana K ElsawwahDepartment of Surgery, Morristown Medical Center, Morristown, NJ, USA.
Zoltan H NemethDepartment of Surgery, Morristown Medical Center, Morristown, NJ, USA. zoltan.nemeth@atlantichealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic and bariatric surgery (MBS) is a successful surgical option for obesity. However, many patients can experience insufficient weight loss and weight regain post-operatively. Glucagon-like peptide-1 (GLP-1) receptor agonists have become available for effective weight loss treatment due to their effects of suppressing appetite, slowing gastric emptying, and promoting fat loss. This systematic review aims to evaluate the efficacy of using GLP-1 agonists to treat insufficient weight loss or regain after metabolic/bariatric surgery. Pooled analysis demonstrated that GLP-1 agonists have a moderate effect on weight loss after failed weight loss or weight regain following MBS, with a Cohen's d-score of 0.470 (p ≤ 0.001). GLP-1 agonists show promise and deserve additional research as part of the standard of care following MBS with insufficient weight loss.

Indexed as

Bariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsObesity, MorbidWeight GainWeight LossHumansTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsBody mass index (BMI)Glucagon-like peptide-1 (GLP-1)Meta-analysisMetabolic and bariatric surgery (MBS)ObesityWeight loss and weight regain

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.